Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

BACKGROUND: Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Rizvi, Naiyer A, Mazières, Julien, Planchard, David, Stinchcombe, Thomas E, Dy, Grace K, Antonia, Scott J, Horn, Leora, Lena, Hervé, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A, Campos, Luis T, Gandara, David R, Levy, Benjamin P, Nair, Suresh G, Zalcman, Gérard, Wolf, Jürgen, Souquet, Pierre-Jean, Baldini, Editta, Cappuzzo, Federico, Chouaid, Christos, Dowlati, Afshin, Sanborn, Rachel, Lopez-Chavez, Ariel, Grohe, Christian, Huber, Rudolf M, Harbison, Christopher T, Baudelet, Christine, Lestini, Brian J, Ramalingam, Suresh S
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5726228/
https://ncbi.nlm.nih.gov/pubmed/25704439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)70054-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados